Tuesday, September 12, 2023 8:08:11 AM
Trial to Assess Multi Cancer Genetic Risk Assessment in General Practice
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce that a Medical Research Future Fund (MRFF) Genomics Health Futures Mission Grant has been awarded to a group of renowned national and international research and charity organizations. The grant will provide funding for the CASSOWARY Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice. GTG is the National Research Partner for trial which is to be led by Professor Jon Emery.
Highlights:
Results from the trial are expected to change the way risk is assessed and reshape the standard of care in general practice for serious disease.
The trial results will inform future policy including the 5-year goal in the Australian Cancer Plan of using genomics for risk-stratified cancer screening.
Results of this study could lead to a revision of national guidelines and improve risk stratification for four of the most common cancers in Australia; breast, colorectal, prostate, and melanoma.
The study will recruit nearly 600 participants from eight general practices across Victoria.
As the sole industry partner, GTG will receive funding to cover the supply of test kits and the analysis of the sample returned.
The project titled, “The CASSOWARY (CAncer genomic riSk ScOres in primARY Care) Trial: a randomised controlled trial of the clinical utility and cost-effectiveness of a multi-cancer polygenic risk score in general practice”. This is a multi-institutional, multidisciplinary collaborative initiative with internationally recognised experts. Disciplines include academic, general practice and primary care trials, clinical genetics and genetic counselling, genetic/cancer epidemiology, health economics and modelling, biostatistics, implementation science, genomic test development and commercialisation, consumer investigators with lived experience of cancer and associate investigators with expertise in cancer policy with Cancer Australia. The Cassowary Trial is a collaboration between international investigators from GTG (Industry partner), University of Melbourne and Queen Mary University of London, The Royal Melbourne Hospital, Royal Marsden NHS Foundation Trust, and the Daffodil Centre.
The study will recruit a targeted cohort to create high quality evidence about the clinical utility and cost-effectiveness of using cancer polygenic risk scores, such as geneType multi-Test to tailor cancer screening and possible treatment in general practice.
Professor Jon Emery, the lead investigator of this study team, has an established history in genomics in Australian general practice and has been involved in national and international screening and cancer risk assessment guidelines. This funding is one of several trials that he leads, “We look forward to extending our work in the space of polygenic risk score implementation in general practice. Over the years, our team has created a framework for risk-assessment implementation in clinical practice, and with each subsequent study we are building our evidence to support a structured, real-world implementation strategy.”
This multi-year utility trial will focus on the implementation of four of geneType’s multi-Test integrated polygenic risk scores: breast, colorectal, prostate, and melanoma. The trial will assess patient and provider behaviour, and assess the economic impact of the resulting behaviour.
GTG’s Director of Scientific Affairs, Erika Spaeth, a co-investigator of the study said, “We are proud of our academic partnerships and honoured to be a part of the growing body of evidence showing the utility of polygenic risk in clinical care. We look forward to the implementation evidence outcomes that will result from this utility study.”
GTG has a strong history of research partnerships with academic institutions, including the University of Melbourne. The company is committed to its collaborative initiatives that support the evolution of predictive population healthcare. GTG’s CEO, Simon Morriss noted, “This is an important step forward for preventive precision medicine. The results from the Cassowary Trial have the ability to support the clinical utility of geneType multi-Test and even more importantly provide compelling evidence for its’ inclusion into National Guidelines and standard of care. The results from this study will be a major leap forward for geneType.”
Authorised for release by the board of directors of Genetic Technologies Limited.
Enquiries
Investor Relations
Adrian Mulcahy
Automic Markets
M: +61 438 630 411
E: adrian.mulcahy@automicgroup.com.au
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com
Recent GENE News
- Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering • GlobeNewswire Inc. • 04/22/2024 07:00:36 PM
- Genetic Technologies Announces $2 Million Registered Direct Offering • GlobeNewswire Inc. • 04/18/2024 04:17:51 PM
- New Precision Oncology Tests to Drive Personalised Therapies and Improved Treatment Outcomes • GlobeNewswire Inc. • 04/17/2024 12:00:00 PM
- GeneType Clinicians’ Adoption Growing - Sales up 5-Fold Year on Year • GlobeNewswire Inc. • 04/16/2024 12:00:00 PM
- GTG to pilot GeneType in Breast Screen centers across the U.S. • GlobeNewswire Inc. • 04/11/2024 12:00:00 PM
- EVENT - Empowering Women Through Knowledge; Humanise Health & GeneType Launch "Know Your Risk” • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- Genetic Technologies’ Digital Strategy Ignites Significant Traction in US Market • GlobeNewswire Inc. • 04/02/2024 12:05:00 PM
- GTG Global Collaborations and Innovation Update • GlobeNewswire Inc. • 03/26/2024 12:00:00 PM
- GENE to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/26/2024 01:00:38 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/15/2024 01:00:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:14:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/31/2024 01:00:25 PM
- Launching our most comprehensive test and expanding into new global markets • GlobeNewswire Inc. • 01/31/2024 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/09/2024 01:00:22 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2024 01:00:16 PM
- Genetic Technologies Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 01/05/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/05/2024 05:15:09 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/28/2023 01:00:23 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/27/2023 01:00:13 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 12/20/2023 10:00:51 PM
- GeneType's Groundbreaking Saliva Test Transforms Early Disease Detection, Paving the Way for Personalized Wellness • GlobeNewswire Inc. • 12/14/2023 01:00:00 PM
- Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change • GlobeNewswire Inc. • 12/12/2023 01:00:00 PM
- Private Hospital Partnership; Expanded Multi-Test for Australian Market and Commercial Partner for Cancer Clinical Trial • GlobeNewswire Inc. • 10/30/2023 12:00:00 PM
- GeneType Predicting Risk of Pancreatic Cancer: Major Breakthrough in Early Detection and Treatment • GlobeNewswire Inc. • 10/18/2023 12:30:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM